Results 201 to 210 of about 2,454,753 (237)

Sustainable valorization of artisanal sour buttermilk using nanofiltration and spray drying. [PDF]

open access: yesFront Nutr
Manik S   +6 more
europepmc   +1 more source

Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis   +4 more
wiley   +1 more source

Rutin Exhibits In-Vitro Anticoagulant Activity in Human Blood Samples by Prolonging Coagulation Pathway Times. [PDF]

open access: yesGlob Adv Integr Med Health
Palikhey A   +5 more
europepmc   +1 more source

Mobile health interventions to improve adherence to oral anticoagulant treatment: A systematic review and critical analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Non‐adherence to oral anticoagulants (OACs) is associated with significant morbidity and mortality. Mobile health (mHealth) interventions have been used to improve medication adherence across the three phases of initiation, implementation and persistence.
Non Davies   +2 more
wiley   +1 more source

An ETH‐LAD trip with unfavourable consequences: A case report

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Numerous analogues of the psychedelic and internationally controlled hallucinogen LSD have been described; however, only a limited number have been systematically investigated. This report presents the first case with an analytically confirmed ingestion of ETH‐LAD (6‐ethyl‐6‐nor‐lysergic acid diethylamide), the N‐ethyl derivative of LSD.
Johannes Nadler   +6 more
wiley   +1 more source

Safety and pharmacokinetics of inhaled aloxistatin: A first‐in‐human phase 1 dose escalation trial

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Aloxistatin (E64d) is a membrane‐permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first‐in‐human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers.
Sebastian Fähndrich   +24 more
wiley   +1 more source

Beyond wound sealing: A dual‐functional adhesive nanofiber membrane promoting coagulation and osteogenesis in extraction sites

open access: yesBMEMat, EarlyView.
Inspired by the suction mechanics of octopus suckers, a dual‐layer nanofiber membrane integrates antibacterial protection, strong wet adhesion, and osteogenic support, offering a bioinspired strategy for effective hemostasis and alveolar bone preservation.
Huijing Ma   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy